WO2002054985A9 - Stent for treating in-stent restenosis - Google Patents
Stent for treating in-stent restenosisInfo
- Publication number
- WO2002054985A9 WO2002054985A9 PCT/US2001/046925 US0146925W WO02054985A9 WO 2002054985 A9 WO2002054985 A9 WO 2002054985A9 US 0146925 W US0146925 W US 0146925W WO 02054985 A9 WO02054985 A9 WO 02054985A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- stent
- combination
- area
- expanded
- openings
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/852—Two or more distinct overlapping stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
- A61F2/07—Stent-grafts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2002/826—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents more than one stent being applied sequentially
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0076—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof multilayered, e.g. laminated structures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2220/00—Fixations or connections for prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2220/0025—Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements
- A61F2220/0033—Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements made by longitudinally pushing a protrusion into a complementary-shaped recess, e.g. held by friction fit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2220/00—Fixations or connections for prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2220/0025—Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements
- A61F2220/005—Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements using adhesives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/006—Additional features; Implant or prostheses properties not otherwise provided for modular
- A61F2250/0063—Nested prosthetic parts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
Definitions
- a stenosis of an artery is a constriction or narrowing of the artery.
- the stenosis may be as a result of the buildup up of cholesterol, fat or other substances.
- a stenosis can be life threatening.
- Stenoses of coronary arteries can diminish the flow of blood to the heart leading to heart damage and, possibly, death.
- a number of methods have been developed for widening arteries which have become stenosed. These methods include stenting, percutaneous transluminal coronary angioplasty (PTCA), coronary artery bypass graft (CABG) procedures and the use of drugs and/or radiation.
- PTCA percutaneous transluminal coronary angioplasty
- CABG coronary artery bypass graft
- stenting has proven to be of particular value in lowering the rate of restenosis or formation of new stenoses following the procedure. Even stented regions of a vessel, however, can restenose.
- Restenosis only occurs in a fraction of patients. It can, however, be difficult to treat in patients in whom it occurs. Restenossis typically occurs within six months to one year of initial treatment of the vessel.
- a number of different techniques have been devised to reduce the likelihood of restenosis in stented regions of a vessel. These techniques include treating the patient with anticoagulant and antiplatelet drugs and smooth muscle cell inhibitors.
- the invention is directed to a combination of a first expanded stent and a second expanded stent disposed within the first stent.
- At least a portion of the second stent has a wall thickness of 0.002 inches or less.
- the entirety of the second stent has a wall thickness of 0.002 inches or less. More desirably, at least a portion of the wall thicknesses is 0.001 inches or less and most desirably, 0.0005 inches or less.
- the first stent may be any suitable stent known in the art.
- the second stent may be any suitable design known in the art.
- stent designs include stents having one or more segments of interconnected struts and stents having one or more segments with cells and openings therethrough.
- the second stent has a tubular surface with openings
- the second stent when expanded has a ratio of the area of the surface to the area of the openings of at least 3:7, desirably at least 1 : 1 and more desirably, at least 3 :2.
- the second stent may be helical or non-helical.
- the second stent may be made of any suitable material whether polymeric or metal or a combination of the two or otherwise. Where the second stent is made of foil, desirably the second stent is only one layer of foil thick. The second stent may be mechanically expandable or self-expanding. In the latter case, the second stent is desirably made of a shape memory material.
- the second stent may comprise a liner or a bioabsorbable membrane.
- the liner may be made of any suitable graft material whether bioabsorbable or not.
- An example of a suitable non-bioabsorbable material is expanded PTFE (ePTFE).
- the bioabsorbable membrane or liner may further comprise a treatment agent.
- the second stent comprises at least a first support and a second support, and a liner extending between the first support and the second support.
- the first and second supports may be hoops.
- the second stent may frictionally engage the first stent.
- the second stent may be attached to the first stent, for example, via one or more hooks.
- the second stent may also be attached to the first stent by being bonded thereto. Where the second stent is self-expanding, it may frictionally engage the first stent by self-expanding against the first stent and applying an outward force against the first stent.
- the invention is directed to a combination of a first stent implanted in a bodily vessel and a second stent disposed within the first stent, where the second stent has a tubular surface with openings therethrough, and the ratio of the area of the surface to the area of the openings when the second stent is expanded is at least 3:7. More desirably, the ratio of the area of the surface to the area of the openings when the second stent is expanded is at least 1:1 and most desirably, the ratio is at least 3:2.
- the invention is also directed to a method of stenting a previously stented region of a bodily vessel where the stented region of the bodily vessel has a first stent therein with a lumen therethrough.
- the method comprises the steps of disposing a second stent in the lumen of the first stent and implanting the second stent in the lumen of the first stent.
- At least a portion of the second stent has a wall thickness of 0.002 inches or less, more desirably, 0.001 inches or less, and most desirably, 0.0005 inches or less.
- the second stent may be of any suitable design, as discussed above and may be mechanically expandable or self-expanding.
- the method may be used to treat a restenosed, previously stented area of a vessel.
- the invention is directed to a method of stenting a previously stented region of a bodily vessel.
- a second stent is disposed in the lumen of an already implanted first stent and implanted therein.
- the second stent has a tubular surface with openings therethrough.
- the ratio of the area of the surface to the area of the openings is at least 3 :7, more desirably 1 : 1 and most desirably, 3 :2.
- the method may be used to treat a restenosed, previously stented area of a vessel.
- the inventive methods may be carried out at any point subsequent to implantation of the first stent using any suitable first stent and second stent as discussed above.
- the first stent will have been implanted in the bodily vessel for a period of time in excess of one month and more desirably, for a period of time in excess of one half year prior to insertion of the second stent.
- the first stent will have been implanted in the bodily vessel for a period of time in excess of one year.
- inventive methods may be preceded and/or followed by one or more steps in which the stented region of the vessel is treated to reduce restenosis.
- a detailed description of the invention in its various embodiments is provided below.
- Fig. 1 shows a perspective view of the inventive stent combination in a vessel with parts cut away.
- Fig. 2 shows a cross-section of the inventive combination of Fig. 1 taken along line 2-2.
- Fig. 3 shows a perspective view of a stent.
- Fig. 4 shows a perspective view of a stent.
- Fig. 5 shows a stent with a membrane.
- Fig. 6 shows a stent having a plurality of supports and a liner.
- Fig. 7 shows a first and second stent with hook
- the invention is directed, in one embodiment, to a combination of a first expanded stent 104 and a second expanded stent 112 disposed within first stent 104 where at least a portion of second stent 112 has a wall thickness 116 of 0.002 inches or less and desirably, 0.001 inches or less. Even more desirably, the wall thickness is 0.0005 inches or less and most desirably, the wall thickness is 0.00025 inches or less.
- the first expanded stent and second expanded stent may optionally be implanted in a bodily vessel 108.
- First stent 104 may be any suitable stent for implantation in a bodily vessel as known in the art.
- the stent comprises one or more serpentine segments 120 as shown in Fig. 3.
- the stent of Fig. 3 comprises a plurality of interconnected segments joined by angled connectors 124.
- the stent may also be formed of a plurality of serpentine segments 120.
- Each serpentine segment comprises a plurality of connected struts 121.
- Adjacent serpentine segments 120 are joined by connectors 124 having one or more bends therein.
- the ends of the connectors may be circumferentially displaced as shown in Fig. 3 or circumferentially aligned with one another.
- Another example of a stent is shown in Fig. 4.
- Stent 104 includes a plurality of interconnected closed cells 109 (one of which is shown shaded). Each closed cell 109 includes an opening 111 therethrough. Stents having at least one segment having closed cells therein, are also disclosed in US 5,733,303, US 6,059,810 and US 6,033,433. Other examples of first stents include those disclosed in commonly assigned, copending US Application 09/437049, spiral or helical stents, stents having a constant diameter when expanded, stents at least a portion of which taper whether an end portion, a middle portion or any other portion and conical stents. The first stent may include one or more radiopaque portions such as is disclosed in commonly assigned copending US Application No.
- First stent 104 may be mechanically expandable, for example balloon expandable or may be self-expandable.
- the first stent may be made of any suitable metallic material or combination of metallic materials including tungsten, aluminum, metal alloys, stainless steel, tantalum, rhenium, titanium, or other types of metallic materials.
- non-metallic materials, composites of metallic and non-metallic materials or other composites may be used.
- Metal-plastic, metal-ceramic composites may be used, and non-metals such as rubbers, ceramics, plastics or other polymers.
- the stent may be optionally made of shape memory materials, whether metal, polymeric or otherwise.
- Second stent 112 desirably is self-expandable and may be made of any suitable material including those specifically disclosed above. Desirable shape memory materials include Nitinol as disclosed in WO 96/26689 and US 6,059,810. The invention also contemplates the use of second stents which mechanically expandable, for example, by balloon. An example of such a stent is disclosed in US 5,733,303. Second stent 112 may also be a foil stent. Where a foil stent is used, the foil stent is desirably only one layer of foil thick. More information about foil stents may be found in US 6,120,535. Second stent 112 may be of any suitable design including the designs discussed above for the first stent.
- the stent comprises one or more serpentine segments such as those shown at 120 in Fig. 3. Adjacent segments may be connected via angled connectors as shown at 124 in Fig. 3.
- the second stent may also be formed of a plurality of serpentine segments joined by connectors having one or more bends therein. The ends of the connectors may be circumferentially aligned with one another or circumferentially displaced from one another.
- the second stent may include a plurality of interconnected closed cells such as those shown at 109 in Fig. 4. Stents having at least one segment having closed cells therein, are also disclosed in US 5,733,303, US 6,059,810 and US 6,033,433.
- a suitable second stent is disclosed in commonly assigned, copending US Application 09/437049 which discloses stents having a microstructure which preferably have about the following dimensions: strut width - 0.00025 - 0.002 inches strut thickness - 0.00025 - 0.004 inches maximum PIN opening - 0.002 - 0.020 inches diameter
- maximum PIN opening is used herein to describe micro openings in which the dimensions specify the largest which can be passed through the cell opening. This applies as noted above to the expanded stent configuration. Typically, as a stent is expanded to larger diameters, the opening becomes larger. It is believed that using a maximum PIN opening specification that the concept of the present invention may be more readily applicable to stents of either open or closed cell geometries.
- a second stent include spiral or helical stents, stents having a constant diameter when expanded, stents at least a portion of which taper whether an end portion, a middle portion or any other portion and conical stents.
- the second stent may include one or more radiopaque portions such as is disclosed in commonly assigned copending US Application No. 09/659571.
- the radiopaque portions of the second stent when expanded may line up with one or more radiopaque portions of the first stent or may displaced from any radiopaque portions of the first stent.
- second stent 112 may comprise an optional liner 128 disposed on the outer surface of the stent or stent segments 120.
- Liner 128 may be any suitable graft material including expanded PTFE (ePTFE).
- Liner 128 may also be a bioabsorbable membrane.
- Second stent 112 may also comprise a plurality of supports 132 with a liner 128 extending therebetween, as shown in Fig. 6.
- supports 132 are in the form of hoops.
- Liner 128 has a thickness of less than 0.002 inches and more desirably, less than 0.001 inches. Even more desirably, the thickness is 0.0005 inches or less and most desirably, the thickness is 0.00025 inches or less.
- Liner 128 may be made of foil or any suitable graft material including bioabsorbable materials and ePTFE.
- the second stent may optionally be attached to the first stent.
- the attachment may be through one or more hooks which may be secured to the first stent.
- the first stent may comprise a plurality of loops for receiving the hooks.
- the hooks and loops operate similar to VELCROTM.
- hooks 136 extending from second stent 112 engage loops 137 extending from first stent 104.
- the hooks may extend from one of the first or the second stent with the loops extending from the other stent.
- the second stent may also be bonded to the first stent via the use of adhesives.
- the second stent may apply an outward force against the first stent and form a friction fit with the first stent such as is the case with a self-expanding stent
- second stent 112 has a tubular surface with openings 111 therethrough, as shown for example in Fig. 4, desirably, the ratio of the area of the surface to the area of the openings at least 3:7 when the second stent is expanded. More desirably, the ratio of the area of the surface to the area of the openings when the second stent is expanded is at least 1:1. Even more desirably, the ratio of the area of the surface to the area of the openings is at least 3 :2. Providing a high ratio of surface area to the area of the openings is desirable in preventing additional restenosis.
- the invention is also directed to the combination of a first stent implanted in a bodily vessel and a second stent disposed within the first stent, as shown, for example, in Fig. 1, where the second stent has a tubular surface with openings therethrough.
- the ratio of the area of the surface to the area of the openings at least 3:7. More desirably, the ratio of the area of the surface to the area of the openings is at least 1:1. Even more desirably, the ratio of the area of the surface to the area of the openings is at least 3:2.
- second stent 112 comprises a treatment agent.
- the treatment agent may be applied to any portion or the entirety of the stent.
- the treatment agent may be applied to the liner.
- the treatment agent may be applied to at least a portion of the struts and/or segments.
- Suitable treatment agents include hydrophilic drugs such as heparin or hirudin to protect against coagulation. Hydrophobic drugs such as prostaglandins or aspirin and vitamin E may be used to protect against platelet activation.
- Vitamin E and other anti oxidants such as sodium ascorbate, phendies, carbazoles, and tocotrienols may be used to protect against oxidation.
- the treatment agent may also include prostaglandins PGI2 or PGE2, RGD peptide, thrombomodulin, TPA (Tissue
- Plasminogen Activator and Urokinase as well as other bioactive proteins.
- Gene therapy agents such as antiplatelet and antibody fragments, for example GB2B3 A may also be provided.
- Other suitable agents include nitric oxide precursor agents, fibrin, Taxol and ticlopidine. Any of the treatment agents disclosed in US 6,074,659 US 6,120,847, US 5,861,168, US 5,800,507 and US 5,693,085 and any of the methodologies disclosed therein for delivering treatment agents may be used. More generally, the treatment materials may include the known antithrombic agents, anti-angiogenesis agents, antibacterial and/or antimicrobial agents and antifungal agents.
- the treatment agent may also be radioactive.
- the radioisotope used in the treatment agent may be an alpha, beta or gamma emitter. Desirably, the half-life of the radioisotope is between 10 hours and 100 days. More desirably, the radioisotope will be a beta emitting isotope such as phosphorous 32, with a 14.3 day half-life and no gamma rays. Additional details concerning such a treatment agent may be found in US 5,722,984 and US 5,871,437.
- radioisotopes for use as treatment agents include the beta emitting isotope gold 198 (half-life 2.7 days) as disclosed in US 5,059,166, beta emitting strontium-89 with a half-life of approximately 50.5 days as disclosed in US 6,129,658, sulfur-35 as disclosed in US 5,919,126 and beta particle-emitting radioactive metals selected from the group consisting of rhenium, copper, dysprosium, yttrium, holmium, praseodymium, lanthanum, samarium, gold, and combinations thereof as disclosed in US 6,077,413.
- the treatment agent comprises a radioisotope
- any suitable method of applying the radioisotope including those disclosed in the above-mentioned patents, may be used.
- the invention is directed to a method of treating restenosis in a stented region of a bodily vessel where the stented region of the bodily vessel has a first stent therein with a lumen therethrough.
- the method comprises the steps of disposing a second stent in the lumen of the first stent and implanting the second stent in the lumen of the first stent.
- At least a portion of the second stent has a wall thickness of 0.002 inches or less and more desirably of 0.001 inches or less. Even more desirably, the wall thickness is 0.0005 inches or less and most desirably, the wall thickness is 0.00025 inches or less.
- the ratio of the area of the surface to the area of the openings when the second stent is expanded is at least 3:7, more desirably, at least 1:1 and most desirably at least 3:2.
- the invention is directed to a method of treating restenosis in a stented region of a bodily vessel, the stented region of the bodily vessel having a first stent therein with a lumen therethrough, the method comprising the steps of disposing and implanting a second stent in the lumen of the first stent.
- the second stent has a tubular surface with openings therethrough. The ratio of the area of the surface to the area of the openings when the second stent is expanded is at least 3 :7, desirably, at least 1 : 1 and most desirably at least 3:2.
- any of the inventive methods disclosed above may employ any of the second stents disclosed above, whether self-expanding, mechanically expandable or otherwise expandable.
- the stent comprises a plurality of struts, such as that shown in Figs. 3 and 4, the struts are desirable of a thickness of 0.001 inches or less, more desirably 0.0005 inches or less and most desirably, 0.00025 inches or less.
- the thinner stents may be desirably be provided in a foil stent as discussed above.
- inventive methods of implanting a second stent within an already implanted first stent may be practiced after the first stent has been implanted for at least a month, two months, six months, a year or more. More generally, the second stent may be implanted at any time subsequent to the deployment of the first stent. Typically, the method will be carried out subsequent to restenosis of the stented region of the vessel.
- any of the inventive methods disclosed herein may also include one or more treatment steps in which the stented region of the vessel is treated to reduce or eliminate restenosis, desirably, prior to insertion of the second stent in the first stent.
- treatment steps in which the stented region of the vessel is treated to reduce or eliminate restenosis, desirably, prior to insertion of the second stent in the first stent.
- Balloon angioplasty a technique in which a balloon is expanded in a stenotic region of a vessel, may be used. Additional details concerning balloon angioplasty may be found in US 6,010,480. Another technique which may be employed involves the use of a thermal catheter comprising a balloon as disclosed in US 4,799,479. Yet another technique which may be used employs both a balloon and a laser as disclosed in US 5,741,246. Other suitable techniques for reducing restenosis involve the use of a laser catheter as disclosed in US 6,106,51. The laser may be an excimer laser, Nd: YAG, holmium, CO 2 laser or any other suitable laser. Techniques in which plaque is mechanically removed from the stented region may also be employed.
- Another treatment modality involves the use of radiation treatment, as disclosed in US 5,833,593.
- Yet another approach involves treatment with a drug which modulates cell growth into the target artery to inhibit the proliferation of smooth muscle cells.
- antiplatelet agents such as aspirin and dipyridamole
- anticoagulants such as heparin
- Other suitable treatment agents are disclosed above.
- inventive combinations and methods may be used for coronary arteries, peripheral arteries, arteries of the neck and intracranial arteries. More generally, the inventive combinations and methods may be used for any vessel of the human body including but not limited to arteries, veins, biliary ducts, urethras, fallopian tubes, bronchial tubes, the trachea and the esophagus.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE60126146T DE60126146T2 (en) | 2001-01-12 | 2001-11-02 | STENT FOR THE TREATMENT OF RESTENOSIS IN A STENT |
JP2002555724A JP4159877B2 (en) | 2001-01-12 | 2001-11-02 | Stent for in-stent restenosis |
CA002437413A CA2437413A1 (en) | 2001-01-12 | 2001-11-02 | Stent for treating in-stent restenosis |
EP01989976A EP1349517B1 (en) | 2001-01-12 | 2001-11-02 | Stent for treating in-stent restenosis |
AU2002228855A AU2002228855B2 (en) | 2001-01-12 | 2001-12-02 | Stent for treating in-stent restenosis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/681,118 | 2001-01-12 | ||
US09/681,118 US20010044650A1 (en) | 2001-01-12 | 2001-01-12 | Stent for in-stent restenosis |
Publications (4)
Publication Number | Publication Date |
---|---|
WO2002054985A2 WO2002054985A2 (en) | 2002-07-18 |
WO2002054985A3 WO2002054985A3 (en) | 2003-05-15 |
WO2002054985A8 WO2002054985A8 (en) | 2003-12-31 |
WO2002054985A9 true WO2002054985A9 (en) | 2004-02-12 |
Family
ID=24733906
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/046925 WO2002054985A2 (en) | 2001-01-12 | 2001-11-02 | Stent for treating in-stent restenosis |
Country Status (8)
Country | Link |
---|---|
US (2) | US20010044650A1 (en) |
EP (2) | EP1349517B1 (en) |
JP (1) | JP4159877B2 (en) |
AT (1) | ATE434426T1 (en) |
AU (1) | AU2002228855B2 (en) |
CA (1) | CA2437413A1 (en) |
DE (2) | DE60139090D1 (en) |
WO (1) | WO2002054985A2 (en) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7204848B1 (en) | 1995-03-01 | 2007-04-17 | Boston Scientific Scimed, Inc. | Longitudinally flexible expandable stent |
US5961545A (en) * | 1997-01-17 | 1999-10-05 | Meadox Medicals, Inc. | EPTFE graft-stent composite device |
US7226475B2 (en) * | 1999-11-09 | 2007-06-05 | Boston Scientific Scimed, Inc. | Stent with variable properties |
US6986786B1 (en) * | 2000-09-11 | 2006-01-17 | Scimed Life Systerms, Inc. | Endovascular prostethic devices having hook and loop structures |
WO2003002243A2 (en) | 2001-06-27 | 2003-01-09 | Remon Medical Technologies Ltd. | Method and device for electrochemical formation of therapeutic species in vivo |
US7708712B2 (en) | 2001-09-04 | 2010-05-04 | Broncus Technologies, Inc. | Methods and devices for maintaining patency of surgically created channels in a body organ |
US20030077310A1 (en) | 2001-10-22 | 2003-04-24 | Chandrashekhar Pathak | Stent coatings containing HMG-CoA reductase inhibitors |
US20030114919A1 (en) * | 2001-12-10 | 2003-06-19 | Mcquiston Jesse | Polymeric stent with metallic rings |
US8021418B2 (en) * | 2003-06-19 | 2011-09-20 | Boston Scientific Scimed, Inc. | Sandwiched radiopaque marker on covered stent |
US7131993B2 (en) * | 2003-06-25 | 2006-11-07 | Boston Scientific Scimed, Inc. | Varying circumferential spanned connectors in a stent |
US8308682B2 (en) | 2003-07-18 | 2012-11-13 | Broncus Medical Inc. | Devices for maintaining patency of surgically created channels in tissue |
US20050038497A1 (en) * | 2003-08-11 | 2005-02-17 | Scimed Life Systems, Inc. | Deformation medical device without material deformation |
US20050203606A1 (en) * | 2004-03-09 | 2005-09-15 | Vancamp Daniel H. | Stent system for preventing restenosis |
EP1604697A1 (en) * | 2004-06-09 | 2005-12-14 | J.A.C.C. GmbH | Implantable device |
US20050278017A1 (en) * | 2004-06-09 | 2005-12-15 | Scimed Life Systems, Inc. | Overlapped stents for scaffolding, flexibility and MRI compatibility |
EP1763327B1 (en) * | 2004-07-02 | 2018-09-12 | Cook Medical Technologies LLC | Balloon / self-expanding stent graft |
US8409167B2 (en) | 2004-07-19 | 2013-04-02 | Broncus Medical Inc | Devices for delivering substances through an extra-anatomic opening created in an airway |
WO2006024491A1 (en) | 2004-08-30 | 2006-03-09 | Interstitial Therapeutics | Methods and compositions for the treatment of cell proliferation |
GB2420976B (en) * | 2004-11-19 | 2006-12-20 | Zvi Finkelstein | Therapeutic implant |
US20060155367A1 (en) * | 2005-01-07 | 2006-07-13 | Hines Richard A | Micro-pleated stent assembly |
US8043366B2 (en) | 2005-09-08 | 2011-10-25 | Boston Scientific Scimed, Inc. | Overlapping stent |
EP1797843A1 (en) * | 2005-12-14 | 2007-06-20 | Thomas Ischinger | Lesion specific stents, also for ostial lesions, and methods of application |
US8840660B2 (en) | 2006-01-05 | 2014-09-23 | Boston Scientific Scimed, Inc. | Bioerodible endoprostheses and methods of making the same |
US8089029B2 (en) | 2006-02-01 | 2012-01-03 | Boston Scientific Scimed, Inc. | Bioabsorbable metal medical device and method of manufacture |
US8048150B2 (en) * | 2006-04-12 | 2011-11-01 | Boston Scientific Scimed, Inc. | Endoprosthesis having a fiber meshwork disposed thereon |
EP2054537A2 (en) | 2006-08-02 | 2009-05-06 | Boston Scientific Scimed, Inc. | Endoprosthesis with three-dimensional disintegration control |
US7988720B2 (en) | 2006-09-12 | 2011-08-02 | Boston Scientific Scimed, Inc. | Longitudinally flexible expandable stent |
EP2210625B8 (en) | 2006-09-15 | 2012-02-29 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis with biostable inorganic layers |
CA2663220A1 (en) | 2006-09-15 | 2008-03-20 | Boston Scientific Limited | Medical devices and methods of making the same |
EP2081616B1 (en) | 2006-09-15 | 2017-11-01 | Boston Scientific Scimed, Inc. | Bioerodible endoprostheses and methods of making the same |
JP2010503494A (en) | 2006-09-15 | 2010-02-04 | ボストン サイエンティフィック リミテッド | Biodegradable endoprosthesis and method for producing the same |
US8002821B2 (en) | 2006-09-18 | 2011-08-23 | Boston Scientific Scimed, Inc. | Bioerodible metallic ENDOPROSTHESES |
US8636791B1 (en) | 2006-11-21 | 2014-01-28 | Seshadri Raju | Venous stent |
US9539124B1 (en) | 2006-11-21 | 2017-01-10 | Seshadri Raju | Venous stent |
ES2506144T3 (en) | 2006-12-28 | 2014-10-13 | Boston Scientific Limited | Bioerodible endoprosthesis and their manufacturing procedure |
JP2008245699A (en) * | 2007-03-29 | 2008-10-16 | Yamaguchi Univ | Stent for gradually releasing drug |
US7637940B2 (en) * | 2007-07-06 | 2009-12-29 | Boston Scientific Scimed, Inc. | Stent with bioabsorbable membrane |
US8052745B2 (en) | 2007-09-13 | 2011-11-08 | Boston Scientific Scimed, Inc. | Endoprosthesis |
US20090105811A1 (en) * | 2007-10-18 | 2009-04-23 | Medtronic, Inc. | Intravascular Devices for Cell-Based Therapies |
US20090138065A1 (en) * | 2007-11-28 | 2009-05-28 | Wilson-Cook Medical Inc. | Double loaded stent delivery system |
US7998192B2 (en) | 2008-05-09 | 2011-08-16 | Boston Scientific Scimed, Inc. | Endoprostheses |
US8236046B2 (en) | 2008-06-10 | 2012-08-07 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis |
US7985252B2 (en) | 2008-07-30 | 2011-07-26 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis |
US8382824B2 (en) | 2008-10-03 | 2013-02-26 | Boston Scientific Scimed, Inc. | Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides |
US20100137973A1 (en) * | 2008-12-02 | 2010-06-03 | Boston Scientific Scimed, Inc. | Layered Bifurcation Stent |
EP2403546A2 (en) | 2009-03-02 | 2012-01-11 | Boston Scientific Scimed, Inc. | Self-buffering medical implants |
EP2496189A4 (en) | 2009-11-04 | 2016-05-11 | Nitinol Devices And Components Inc | Alternating circumferential bridge stent design and methods for use thereof |
US8668732B2 (en) | 2010-03-23 | 2014-03-11 | Boston Scientific Scimed, Inc. | Surface treated bioerodible metal endoprostheses |
US9301864B2 (en) | 2010-06-08 | 2016-04-05 | Veniti, Inc. | Bi-directional stent delivery system |
US8864811B2 (en) | 2010-06-08 | 2014-10-21 | Veniti, Inc. | Bi-directional stent delivery system |
US20120035706A1 (en) * | 2010-08-03 | 2012-02-09 | Cook Medical Technologies Llc | Blood perfusion device delivery system |
US9233014B2 (en) | 2010-09-24 | 2016-01-12 | Veniti, Inc. | Stent with support braces |
EP2624791B1 (en) | 2010-10-08 | 2017-06-21 | Confluent Medical Technologies, Inc. | Alternating circumferential bridge stent design |
JP5575327B2 (en) * | 2011-03-08 | 2014-08-20 | 株式会社パイオラックスメディカルデバイス | Stent |
JP2014521381A (en) | 2011-05-13 | 2014-08-28 | ブロンカス テクノロジーズ, インコーポレイテッド | Methods and devices for tissue ablation |
US8709034B2 (en) | 2011-05-13 | 2014-04-29 | Broncus Medical Inc. | Methods and devices for diagnosing, monitoring, or treating medical conditions through an opening through an airway wall |
US9387099B2 (en) | 2011-08-04 | 2016-07-12 | Cook Medical Technologies Llc | Non-woven helical wire stent |
EP2559400A1 (en) * | 2011-08-19 | 2013-02-20 | Abbott Laboratories Vascular Enterprises Limited | Stent graft with alternating rings |
WO2013078235A1 (en) | 2011-11-23 | 2013-05-30 | Broncus Medical Inc | Methods and devices for diagnosing, monitoring, or treating medical conditions through an opening through an airway wall |
CA3095731C (en) | 2011-12-06 | 2023-02-07 | Aortic Innovations Llc | Device for endovascular aortic repair and method of using the same |
US9238090B1 (en) | 2014-12-24 | 2016-01-19 | Fettech, Llc | Tissue-based compositions |
CN104490502A (en) * | 2014-12-25 | 2015-04-08 | 周玉杰 | Biological absorbable membrane-covered stent for treating coronary artery perforation |
DE102018105925A1 (en) * | 2018-03-14 | 2019-09-19 | Malte Neuss | double stent |
Family Cites Families (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3577607A (en) * | 1967-06-19 | 1971-05-04 | Ikoma Orimono Co Ltd | Separable fastening fabric |
US4416028A (en) * | 1981-01-22 | 1983-11-22 | Ingvar Eriksson | Blood vessel prosthesis |
US4580568A (en) * | 1984-10-01 | 1986-04-08 | Cook, Incorporated | Percutaneous endovascular stent and method for insertion thereof |
US4799479A (en) | 1984-10-24 | 1989-01-24 | The Beth Israel Hospital Association | Method and apparatus for angioplasty |
US5059166A (en) | 1989-12-11 | 1991-10-22 | Medical Innovative Technologies R & D Limited Partnership | Intra-arterial stent with the capability to inhibit intimal hyperplasia |
US5064435A (en) * | 1990-06-28 | 1991-11-12 | Schneider (Usa) Inc. | Self-expanding prosthesis having stable axial length |
DE69231787T2 (en) * | 1991-01-28 | 2001-08-02 | Matsushita Electric Ind Co Ltd | Medical article and process for its manufacture |
US5254133A (en) * | 1991-04-24 | 1993-10-19 | Seid Arnold S | Surgical implantation device and related method of use |
US5147370A (en) * | 1991-06-12 | 1992-09-15 | Mcnamara Thomas O | Nitinol stent for hollow body conduits |
US5811447A (en) | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
CA2380683C (en) * | 1991-10-28 | 2006-08-08 | Advanced Cardiovascular Systems, Inc. | Expandable stents and method for making same |
US5211658A (en) * | 1991-11-05 | 1993-05-18 | New England Deaconess Hospital Corporation | Method and device for performing endovascular repair of aneurysms |
FR2683449A1 (en) * | 1991-11-08 | 1993-05-14 | Cardon Alain | ENDOPROTHESIS FOR TRANSLUMINAL IMPLANTATION. |
DE69326631T2 (en) | 1992-03-19 | 2000-06-08 | Medtronic Inc | Intraluminal expansion device |
US5540712A (en) * | 1992-05-01 | 1996-07-30 | Nitinol Medical Technologies, Inc. | Stent and method and apparatus for forming and delivering the same |
WO1993022986A1 (en) * | 1992-05-08 | 1993-11-25 | Schneider (Usa) Inc. | Esophageal stent and delivery tool |
US5441515A (en) * | 1993-04-23 | 1995-08-15 | Advanced Cardiovascular Systems, Inc. | Ratcheting stent |
US5861168A (en) | 1993-06-11 | 1999-01-19 | The Board Of Trustees Of The Leland Stanford Junior University | Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury |
US5746745A (en) | 1993-08-23 | 1998-05-05 | Boston Scientific Corporation | Balloon catheter |
US5609627A (en) * | 1994-02-09 | 1997-03-11 | Boston Scientific Technology, Inc. | Method for delivering a bifurcated endoluminal prosthesis |
US5733303A (en) | 1994-03-17 | 1998-03-31 | Medinol Ltd. | Flexible expandable stent |
US5741246A (en) | 1996-04-15 | 1998-04-21 | Prescott; Marvin A. | Method and apparatus for laser balloon angioplasty treatment of medical conditions |
CA2188563C (en) | 1994-04-29 | 2005-08-02 | Andrew W. Buirge | Stent with collagen |
US5723003A (en) * | 1994-09-13 | 1998-03-03 | Ultrasonic Sensing And Monitoring Systems | Expandable graft assembly and method of use |
CA2175720C (en) * | 1996-05-03 | 2011-11-29 | Ian M. Penn | Bifurcated stent and method for the manufacture and delivery of same |
US7204848B1 (en) * | 1995-03-01 | 2007-04-17 | Boston Scientific Scimed, Inc. | Longitudinally flexible expandable stent |
US6818014B2 (en) * | 1995-03-01 | 2004-11-16 | Scimed Life Systems, Inc. | Longitudinally flexible expandable stent |
US5667523A (en) * | 1995-04-28 | 1997-09-16 | Impra, Inc. | Dual supported intraluminal graft |
US6059810A (en) | 1995-05-10 | 2000-05-09 | Scimed Life Systems, Inc. | Endovascular stent and method |
US5669924A (en) * | 1995-10-26 | 1997-09-23 | Shaknovich; Alexander | Y-shuttle stent assembly for bifurcating vessels and method of using the same |
US5833593A (en) * | 1995-11-09 | 1998-11-10 | United States Surgical Corporation | Flexible source wire for localized internal irradiation of tissue |
US5865723A (en) * | 1995-12-29 | 1999-02-02 | Ramus Medical Technologies | Method and apparatus for forming vascular prostheses |
US5722984A (en) | 1996-01-16 | 1998-03-03 | Iso Stent, Inc. | Antithrombogenic radioactive coating for an intravascular stent |
EP0795304B1 (en) * | 1996-03-10 | 2004-05-19 | Terumo Kabushiki Kaisha | Implanting stent |
JP4636634B2 (en) * | 1996-04-26 | 2011-02-23 | ボストン サイエンティフィック サイムド,インコーポレイテッド | Intravascular stent |
US5617878A (en) * | 1996-05-31 | 1997-04-08 | Taheri; Syde A. | Stent and method for treatment of aortic occlusive disease |
US5755773A (en) * | 1996-06-04 | 1998-05-26 | Medtronic, Inc. | Endoluminal prosthetic bifurcation shunt |
US5769884A (en) * | 1996-06-27 | 1998-06-23 | Cordis Corporation | Controlled porosity endovascular implant |
US6120535A (en) * | 1996-07-29 | 2000-09-19 | Radiance Medical Systems, Inc. | Microporous tubular prosthesis |
US5836896A (en) | 1996-08-19 | 1998-11-17 | Angiosonics | Method of inhibiting restenosis by applying ultrasonic energy |
US6007573A (en) * | 1996-09-18 | 1999-12-28 | Microtherapeutics, Inc. | Intracranial stent and method of use |
US5807404A (en) * | 1996-09-19 | 1998-09-15 | Medinol Ltd. | Stent with variable features to optimize support and method of making such stent |
US6261320B1 (en) * | 1996-11-21 | 2001-07-17 | Radiance Medical Systems, Inc. | Radioactive vascular liner |
US5871437A (en) | 1996-12-10 | 1999-02-16 | Inflow Dynamics, Inc. | Radioactive stent for treating blood vessels to prevent restenosis |
DE19703482A1 (en) * | 1997-01-31 | 1998-08-06 | Ernst Peter Prof Dr M Strecker | Stent |
US5882329A (en) * | 1997-02-12 | 1999-03-16 | Prolifix Medical, Inc. | Apparatus and method for removing stenotic material from stents |
US5853419A (en) * | 1997-03-17 | 1998-12-29 | Surface Genesis, Inc. | Stent |
US5824052A (en) * | 1997-03-18 | 1998-10-20 | Endotex Interventional Systems, Inc. | Coiled sheet stent having helical articulation and methods of use |
US5843168A (en) * | 1997-03-31 | 1998-12-01 | Medtronic, Inc. | Double wave stent with strut |
US6033433A (en) | 1997-04-25 | 2000-03-07 | Scimed Life Systems, Inc. | Stent configurations including spirals |
US6451049B2 (en) * | 1998-04-29 | 2002-09-17 | Sorin Biomedica Cardio, S.P.A. | Stents for angioplasty |
US5957929A (en) * | 1997-05-02 | 1999-09-28 | Micro Therapeutics, Inc. | Expandable stent apparatus and method |
FR2762777B1 (en) * | 1997-05-05 | 1999-10-22 | Patrick Sabaria | VASCULAR AND CORONARY EXTENDERS, USUALLY DESIGNATED UNDER THE NAME OF "STENT" |
DE19720115C2 (en) * | 1997-05-14 | 1999-05-20 | Jomed Implantate Gmbh | Stent graft |
US5913895A (en) * | 1997-06-02 | 1999-06-22 | Isostent, Inc. | Intravascular stent with enhanced rigidity strut members |
US5800525A (en) * | 1997-06-04 | 1998-09-01 | Vascular Science, Inc. | Blood filter |
US5919126A (en) | 1997-07-07 | 1999-07-06 | Implant Sciences Corporation | Coronary stent with a radioactive, radiopaque coating |
US5951599A (en) * | 1997-07-09 | 1999-09-14 | Scimed Life Systems, Inc. | Occlusion system for endovascular treatment of an aneurysm |
US6165195A (en) * | 1997-08-13 | 2000-12-26 | Advanced Cardiovascylar Systems, Inc. | Stent and catheter assembly and method for treating bifurcations |
US5976182A (en) * | 1997-10-03 | 1999-11-02 | Advanced Cardiovascular Systems, Inc. | Balloon-expandable, crush-resistant locking stent and method of loading the same |
US5980565A (en) * | 1997-10-20 | 1999-11-09 | Iowa-India Investments Company Limited | Sandwich stent |
US6033435A (en) * | 1997-11-03 | 2000-03-07 | Divysio Solutions Ulc | Bifurcated stent and method for the manufacture and delivery of same |
EP1625833A3 (en) * | 1997-11-25 | 2010-09-22 | TriVascular2, Inc. | Layered endovascular graft |
US6129658A (en) | 1997-12-10 | 2000-10-10 | Varian Associates, Inc. | Method and apparatus creating a radioactive layer on a receiving substrate for in vivo implantation |
US6165209A (en) * | 1997-12-15 | 2000-12-26 | Prolifix Medical, Inc. | Vascular stent for reduction of restenosis |
US6077413A (en) | 1998-02-06 | 2000-06-20 | The Cleveland Clinic Foundation | Method of making a radioactive stent |
US5938697A (en) * | 1998-03-04 | 1999-08-17 | Scimed Life Systems, Inc. | Stent having variable properties |
US6063111A (en) * | 1998-03-31 | 2000-05-16 | Cordis Corporation | Stent aneurysm treatment system and method |
US6099559A (en) * | 1998-05-28 | 2000-08-08 | Medtronic Ave, Inc. | Endoluminal support assembly with capped ends |
US6015433A (en) * | 1998-05-29 | 2000-01-18 | Micro Therapeutics, Inc. | Rolled stent with waveform perforation pattern |
US6036725A (en) * | 1998-06-10 | 2000-03-14 | General Science And Technology | Expandable endovascular support device |
US6106515A (en) | 1998-08-13 | 2000-08-22 | Intraluminal Therapeutics, Inc. | Expandable laser catheter |
US6099455A (en) * | 1998-11-25 | 2000-08-08 | Isostent, Inc. | Radioisotope stent with non-radioactive end sections |
US6120847A (en) | 1999-01-08 | 2000-09-19 | Scimed Life Systems, Inc. | Surface treatment method for stent coating |
US6325825B1 (en) * | 1999-04-08 | 2001-12-04 | Cordis Corporation | Stent with variable wall thickness |
US6503556B2 (en) * | 2000-12-28 | 2003-01-07 | Advanced Cardiovascular Systems, Inc. | Methods of forming a coating for a prosthesis |
US6325823B1 (en) * | 1999-10-29 | 2001-12-04 | Revasc Corporation | Endovascular prosthesis accommodating torsional and longitudinal displacements and methods of use |
US6428569B1 (en) * | 1999-11-09 | 2002-08-06 | Scimed Life Systems Inc. | Micro structure stent configurations |
US6537310B1 (en) * | 1999-11-19 | 2003-03-25 | Advanced Bio Prosthetic Surfaces, Ltd. | Endoluminal implantable devices and method of making same |
WO2001053559A1 (en) * | 2000-01-24 | 2001-07-26 | Smart Therapeutics, Inc. | Thin-film shape memory alloy device and method |
US6312463B1 (en) * | 2000-02-01 | 2001-11-06 | Endotex Interventional Systems, Inc. | Micro-porous mesh stent with hybrid structure |
US6986786B1 (en) * | 2000-09-11 | 2006-01-17 | Scimed Life Systerms, Inc. | Endovascular prostethic devices having hook and loop structures |
US6752825B2 (en) * | 2001-10-02 | 2004-06-22 | Scimed Life Systems, Inc | Nested stent apparatus |
-
2001
- 2001-01-12 US US09/681,118 patent/US20010044650A1/en not_active Abandoned
- 2001-11-02 CA CA002437413A patent/CA2437413A1/en not_active Abandoned
- 2001-11-02 AT AT07000600T patent/ATE434426T1/en not_active IP Right Cessation
- 2001-11-02 WO PCT/US2001/046925 patent/WO2002054985A2/en active IP Right Grant
- 2001-11-02 DE DE60139090T patent/DE60139090D1/en not_active Expired - Lifetime
- 2001-11-02 JP JP2002555724A patent/JP4159877B2/en not_active Expired - Fee Related
- 2001-11-02 EP EP01989976A patent/EP1349517B1/en not_active Expired - Lifetime
- 2001-11-02 EP EP07000600A patent/EP1785109B1/en not_active Expired - Lifetime
- 2001-11-02 DE DE60126146T patent/DE60126146T2/en not_active Expired - Lifetime
- 2001-12-02 AU AU2002228855A patent/AU2002228855B2/en not_active Ceased
-
2008
- 2008-07-25 US US12/180,340 patent/US20080288049A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DE60126146T2 (en) | 2007-11-15 |
WO2002054985A2 (en) | 2002-07-18 |
WO2002054985A3 (en) | 2003-05-15 |
WO2002054985A8 (en) | 2003-12-31 |
EP1349517A2 (en) | 2003-10-08 |
AU2002228855B2 (en) | 2006-10-05 |
JP2004522494A (en) | 2004-07-29 |
US20010044650A1 (en) | 2001-11-22 |
ATE434426T1 (en) | 2009-07-15 |
CA2437413A1 (en) | 2002-07-18 |
JP4159877B2 (en) | 2008-10-01 |
EP1349517B1 (en) | 2007-01-17 |
EP1785109A3 (en) | 2007-05-30 |
EP1785109B1 (en) | 2009-06-24 |
EP1785109A2 (en) | 2007-05-16 |
DE60139090D1 (en) | 2009-08-06 |
US20080288049A1 (en) | 2008-11-20 |
DE60126146D1 (en) | 2007-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1349517B1 (en) | Stent for treating in-stent restenosis | |
AU2002228855A1 (en) | Stent for treating in-stent restenosis | |
JP2004522494A6 (en) | Stent for in-stent restenosis | |
JP2940859B2 (en) | Shape memory lock mechanism for intravascular stent | |
US8740973B2 (en) | Polymer biodegradable medical device | |
US8100963B2 (en) | Biodegradable device | |
JP5523331B2 (en) | Stent with helical channel for drug delivery | |
US7803181B2 (en) | Ostial stent | |
US7959669B2 (en) | Bifurcated stent with open ended side branch support | |
US9339403B2 (en) | Medical adhesive for medical devices | |
US20070179599A1 (en) | Vascular protective device | |
US20050278011A1 (en) | Stent delivery system | |
US20030191523A1 (en) | Articulated expandable intraluminal stent | |
US20060271161A1 (en) | Selective treatment of stent side branch petals | |
WO2004064911A1 (en) | Stent for percutaneous coronary intervention, coated with vascular restenosis prevention drug | |
JP2009507561A (en) | Crown stent assembly | |
JP2011504788A (en) | Bifurcated stent with drug wells for treatment of specific mouth, carina, and side branches | |
US20100010618A1 (en) | Overlapping Stent | |
US20140144001A1 (en) | Stent having function elements | |
WO2002100473A1 (en) | Stent and delivery catheter |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002228855 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2437413 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002555724 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001989976 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001989976 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
COP | Corrected version of pamphlet |
Free format text: PAGES 1/5-5/5, DRAWINGS, REPLACED BY NEW PAGES 1/4-4/4; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001989976 Country of ref document: EP |